InsiderSignal.AI

InsiderSignal.ai

MBX - Mbx Biosciences, Inc.

Insider Purchase by Hoerter Steven L. (Dir)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

4 months ago, Hoerter Steven L., serving as Dir at Mbx Biosciences, Inc. (MBX), purchased 20,000 shares at $13.25 per share, for a total transaction value of $264,984.00. Following this transaction, Hoerter Steven L. now holds 20,000 shares of MBX.

The trade was executed on Friday, October 17, 2025 and publicly disclosed via SEC Form 4 filing on Monday, October 20, 2025, 3 days after the trade was made.

Mbx Biosciences, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Hoerter Steven L.

Dir

Steven L. Hoerter (age 54) is a seasoned biopharmaceutical executive serving as Chairman of the Board at MBX Biosciences, Inc. (MBX), a clinical-stage company focused on peptide therapeutics for endocrine and metabolic diseases, since April 2025[[1]](https://fintool.com/app/research/companies/CCCC/people/steven-hoerter)[[2]](https://mbxbio.com/about-us/)[[3]](https://www.sec.gov/Archives/edgar/data/1776111/000095017025051371/mbx-20250407.htm). He recently joined as a Director and has been involved in insider trading activities at MBX[[1]](https://fintool.com/app/research/companies/CCCC/people/steven-hoerter). Hoerter brings extensive commercial expertise, highlighted by his tenure as President & CEO of Deciphera Pharmaceuticals from March 2019 to October 2024, where he led the company through its acquisition by Ono Pharmaceutical, and prior roles as Chief Commercial Officer at Agios Pharmaceuticals (2016–2019) and Clovis Oncology (2015–2016), along with senior positions at Roche/Genentech, Chiron, and Eli Lilly[[1]](https://fintool.com/app/research/companies/CCCC/people/steven-hoerter). Currently, Hoerter also serves as an independent Class II Director at C4 Therapeutics (CCCC) since November 2024, chairing the Organization, Leadership and Compensation Committee and joining the Audit Committee in 2025, and as a Director at ORIC Pharmaceuticals since August 2021[[1]](https://fintool.com/app/research/companies/CCCC/people/steven-hoerter). His educational background includes a B.A. from Bucknell University, an M.B.A. from Tilburg University, and an M.S. in management from Purdue University[[1]](https://fintool.com/app/research/companies/CCCC/people/steven-hoerter).

View full insider profile →

Trade Price

$13.25

Quantity

20,000

Total Value

$264,984.00

Shares Owned

20,000

Trade Date

Friday, October 17, 2025

128 days ago

SEC Filing Date

Monday, October 20, 2025

Filed 3 days after trade

HEALTHCAREBIOTECHNOLOGY

About Mbx Biosciences, Inc.

Company Overview

No company information available
View news mentioning MBX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/849320

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime